Expression of transferrin receptors in phytohemagglutinin-stimulated human T-lymphocytes. Evidence for a three-step model.
Resting human T-lymphocytes show an elevated intracellular concentration of ferritin, whereas transferrin receptors are not detectable. Stimulation by phytohemagglutinin markedly lowers their ferritin content, while inducing the synthesis of transferrin receptors. Addition of iron salts (ferric ammonium citrate) in activated T-lymphocyte cultures causes a marked enhancement of both [3H]uridine and [3H]thymidine incorporation. Nevertheless, it also induces a concentration-dependent decrease in transferrin receptor synthesis, associated with a marked rise of ferritin production. Hemin treatment exerts the same effects. Addition of picolinic acid in phytohemagglutinin-stimulated cultures causes a decrease of [3H]thymidine incorporation, whereas transferrin expression is markedly enhanced. The action of iron salts and chelators is specific for transferrin receptors, since the expression of other membrane markers of activated human T-lymphocytes (interleukin-2 receptor, insulin receptor, and HLA-DR antigen) is not modified by treatment with iron or picolinic acid. These observations suggest that expression of transferrin receptors in activated T-lymphocytes is specifically modulated by their intracellular iron level, rather than their proliferative rate. Addition of picolinic acid to resting T-lymphocytes in the absence of mitogen induces a marked decrease of their ferritin content, but not the appearance of transferrin receptors. On the basis of these results, we suggest a three-step model: (a) in resting T-lymphocytes, the gene for transferrin receptor is apparently "closed," in that it is not expressed under both normal conditions and following iron deprivation. (b) After mitogen stimulus, T-lymphocytes are reprogrammed into cell cycle progression, which necessarily entails synthesis of transferrin receptors (c) Expression of these receptors is modulated by the intracellular iron level, rather than the rate of proliferation per se.
D005290:Ferric Compounds / Q000494:pharmacology; D005293:Ferritins / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D006418:Heme / Q000494:pharmacology; D006801:Humans; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D010835:Phytohemagglutinins / Q000494:pharmacology*; D010848:Picolinic Acids / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000096:biosynthesis*; D011971:Receptors, Immunologic / Q000032:analysis; D015375:Receptors, Interleukin-2; D011990:Receptors, Transferrin; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014529:Uridine / Q000378:metabolism
D005290:Ferric Compounds; D010835:Phytohemagglutinins; D010848:Picolinic Acids; D000644:Quaternary Ammonium Compounds; D011956:Receptors, Cell Surface; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2; D011990:Receptors, Transferrin; D006418:Heme; D005293:Ferritins; C030614:picolinic acid; C013531:ferric ammonium citrate; D013936:Thymidine; D014529:Uridine